FORA Capital’s Nektar Therapeutics NKTR Stock Holding History

FORA Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,761	Closed	-$232K	–	549
2025 Q4	$232K	Buy	+5,761	New	+$322K	0.03%	388
2020 Q3	–	Sell	-550	Closed	-$191K	–	877
2020 Q2	$191K	Buy	+550	New	+$172K	0.07%	354

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FORA Capital's NKTR Position: Q1 2026 in Review

FORA Capital sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 5,761 shares — an estimated $232K sold.

FORA Capital first reported a position in NKTR in Q2 2020 and held it in 2 quarters. The position peaked at $232K in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

FORA Capital reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
FORA Capital sold 5,761 Nektar Therapeutics shares in Q1 2026, an estimated $232K.
FORA Capital first reported a position in Nektar Therapeutics in Q2 2020 and held it in 2 quarters.
FORA Capital's Nektar Therapeutics position peaked at $232K in Q4 2025.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.